Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor

被引：635

作者：

Butrynski, James E. ^{[1
,2
]}

D'Adamo, David R. ^{[5
]}

Hornick, Jason L. ^{[2
,3
]}

Dal Cin, Paola ^{[3
]}

Antonescu, Cristina R. ^{[5
]}

Jhanwar, Suresh C. ^{[5
]}

Ladanyi, Marc ^{[5
]}

Capelletti, Marzia ^{[2
]}

Rodig, Scott J. ^{[2
,3
]}

Ramaiya, Nikhil

Kwak, Eunice L. ^{[2
,4
]}

Clark, Jeffrey W. ^{[2
,4
]}

Wilner, Keith D. ^{[6
]}

Christensen, James G. ^{[6
]}

Jaenne, Pasi A. ^{[2
]}

Maki, Robert G. ^{[5
]}

Demetri, George D. ^{[1
,2
]}

Shapiro, Geoffrey I. ^{[2
,7
]}

机构：

[1] Dana Farber Harvard Canc Ctr, Ludwig Ctr, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

[3] Brigham & Womens Hosp, Boston, MA 02115 USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[6] Pfizer Global Res & Dev, La Jolla, CA USA

[7] Dana Farber Canc Inst, Early Drug Dev Ctr, Boston, MA 02115 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2010年 / 363卷 / 18期

基金：

美国国家卫生研究院;

关键词：

ANAPLASTIC LYMPHOMA; KINASE; EXPRESSION; INHIBITOR; IMATINIB; FUSION; 2P23; GENE;

D O I：

10.1056/NEJMoa1007056

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the ALK translocation. These results support the dependence of ALK-rearranged tumors on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumor.

引用

页码：1727 / 1733

页数：7

共 25 条

[1] Successful preoperative treatment of pediatric bladder inflammatory myofibroblastic tumor with anti-inflammatory therapy [J].

Berger, Alisa ;

Kim, Christina ;

Hagstrom, Nathan ;

Ferrer, Fernando .

UROLOGY, 2007, 70 (02) :372.e13-372.e15

[2] Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma [J].

Christensen, James G. ;

Zou, Helen Y. ;

Arango, Maria E. ;

Li, Qiuhua ;

Lee, Joseph H. ;

McDonnell, Scott R. ;

Yamazaki, Shinji ;

Alton, Gordon R. ;

Mroczkowski, Barbara ;

Los, Gerrit .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) :3314-3322

[3] Inflammatory myofibroblastic tumor - Comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases [J].

Coffin, Cheryl M. ;

Hornick, Jason L. ;

Fletcher, Christopher D. M. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (04) :509-520

[4] ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor [J].

Coffin, CM ;

Patel, A ;

Perkins, S ;

Elenitoba-Johnson, KSJ ;

Perlman, E ;

Griffin, CA .

MODERN PATHOLOGY, 2001, 14 (06) :569-576

[5] EXTRAPULMONARY INFLAMMATORY MYOFIBROBLASTIC TUMOR (INFLAMMATORY PSEUDOTUMOR) - A CLINICOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY OF 84 CASES [J].

COFFIN, CM ;

WATTERSON, J ;

PRIEST, JR ;

DEHNER, LP .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1995, 19 (08) :859-872

[6] Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor - A comparative immunohistochemical study [J].

Cook, JR ;

Dehner, LP ;

Collins, MH ;

Ma, ZG ;

Morris, SW ;

Coffin, CM ;

Hill, DA .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (11) :1364-1371

[7] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[8] Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer [J].

Engelman, Jeffrey A. ;

Jaenne, Pasi A. .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :2895-2899

[9]

Giuriato S, 2007, CANCER BIOL THER, V6, P1318

[10] Inflammatory myofibroblastic tumours: where are we now? [J].

Gleason, B. C. ;

Hornick, J. L. .

JOURNAL OF CLINICAL PATHOLOGY, 2008, 61 (04) :428-437

← 1 2 3 →